secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001093557-24-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom reports preliminary Q4 revenue ≥$1.03B (+26% YoY); FY2024 guidance $4.15-4.35B
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue at least $1.030B, up 26% YoY; FY2023 revenue ~$3.62B (+24%).
- FY2024 revenue guidance $4.15-4.35B, representing organic growth of 16-21%.
- Non-GAAP gross profit margin guidance 63-64% for FY2024; operating margin ~20%.
- Submitted Stelo glucose sensor for type 2 non-insulin users to FDA; expected U.S. launch summer 2024.
- U.S. Q4 revenue ~$765M (+26% YoY); international ~$265M (+27% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/dxcm-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001093557-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer